Urinary tract infection is a common medical .problem in women, and is particularly important in pregnancy because of the potential adverse effect on the mother and fetus. The prevalence of asymptomatic bacteriuria ranges from 2 to 10% (Brumfitt 1981 ; Harris & Gilstrap 1981 ; Lenke et al. 1983; Little 1966; McFadyen et al. 1973 ; Savage et al. 1967 ). This rate approximates to that in sexually active nonpregnant women (Drazancic et al. 1989; Editorial 1985; Kass 1960a; National Institute of Health 1983; Nnatu et al. 1989) . Golan et al. (1989) observed that 5.9%of normal pregnant women, and 60% of pregnant women with diabetes or with a history of previous urinary tract infection, have asymptomatic bacteriuria. Certain features, such as history of past urinary tract infection, chronic renal disease, and diabetes mellitus may suggest a higher chance of symptomatic infection. Between 23 and 40% of these bacteriuric women develop acute pyelonephritis later in pregnancy (Brumfitt 198I; Kunin 1987; Lenke et al. 1983; Little 1966; McFadyen et al. 1973; Savage et al. 1967) . Acute pyelonephritis occurs in two-thirds of women with prenatal bacteriuria, and is more frequent in the second and third trimester; a history of past urinary tract infection increases the risk (Golan et al. 1989) . Acute cystitis usually occurs in the second trimester and most commonly arises in patients without a positive antenatal screening culture (Harris & Gilstrap 198I) . Golan et al. (1989) found only onethird of pregnant woman with cystitis had bacteriuria during the prenatal visit. It appears that antenatal screening, urine cultures, and treatment may not reduce attacks of acute cystitis.
Most investigators recommend prenatal screening and treatment of bacteriuria to reduce the risk of acute pyelonephritis during the latter stage of pregnancy (Kass & Zinner 1973; McNeeley 1988; Krieger 1986; Marchant 1978; Patterson & Andriole 1987; Zhanel et aI. 1990 ). However, screening is not universally accepted. Campbell-Brown et aI. (1987) asked whether screening for bacteriuria was worthwhile. They found that 198 of 4470 pregnant women (4.4%) surveyed had asymptomatic bacteriuria during the initial survey. I 19 patients (2.7%) were confirmed when a second sample was obtained. Screening and treatment prevented only 6 cases of symptomatic infection. Other investigators believe that early antenatal screening and treatment will potentially reduce the clinical infection rate by 66% (Editorial 1985; Golan et aI. 1989) . Platt (1987) reported a marked increase in relative risk for acute pyelonephritis, and a slight increase in relative risk in preterm complications, in pregnant women with asymptomatic bacteriuria. When a pregnant woman has asymptomatic bacteriuria and has a history of previous urinary tract infection, she has a 10-foldgreater chance of developing symptomatic disease than a woman lacking either history, and a 4-fold greater risk compared with a 973 woman with asymptomatic alone (Chng & Hall 1982) . The risk is reduced with treatment (Stamey 1980; Platt 1987) .
This review emphasises the treatment of asymptomatic and clinically symptomatic urinary tract infection in pregnancy, and long and short course therapy for pregnant women with asymptomatic bacteriuria.
Diagnosis
Ideally, all pregnant women should be screened for bacteriuria at their initial visit. Urine should not be collected by catheter to avoid introducing bacteria into the bladder. Recovery of 10 5 colony forming units per ml (cfu/ml) of urine obtained by midstream clean catch technique is the most commonly used screening criterion. In nonpregnant women with asymptomatic bacteriuria, the probability of a second specimen containing greater than 10 5 cfu/ml ofthe same Gram-negative organism is 67% for voided specimen and 90% for catheterised specimen (Kass 1960b) . In women with symptomatic urinary tract infections such as acute cystitis or pyelonephritis, 100 cfu/ml is considered significant (Johnson & Stamm 1989) . When catheterised urine is used, any count greater than 100 cfu/ml is considered significant (Stark & Maki 1984) . Although it is invasive, suprapubic aspiration of bladder urine has been found to be safe and is preferred by some investigators (Campbell-Brown et aI. 1987) . Because suprapubic aspiration is less likely to be contaminated, the presence of any bacteria is considered significant. However, most investigators continue to use the midstream technique because it is more convenient and noninvasive (Patterson & Andriole 1987) .
Microbiology
The microorganisms which cause bacteriuria in pregnancy are similar to those in nonpregnant women (Kass & Zinner 1973; Patterson & Andriole 1987) . Escherichia coli is by far the most common organism isolated in both symptomatic and asymptomatic women. Other enteric organ- 
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Asymptomatic Bacteriuria
Most clinicians recommend antimicrobial therapy for symptomatic and asymptomatic urinary tract infection in pregnancy (Patterson & Andriole 1987; Pedler & Bint 1987; Zhanel et al. 1990 ). The question of short versus longer term treatment is still the subject of some debate , with short course therapy in women with asymptomatic bacteriuria not universally accepted. Table I shows some of the experience with different antimicrobial agents published in the past decade.
Campbell-Brown and McFadyen (1983) treated 37 patients with cefalexin 3g. Patients with proven recurrent urinary tract infection or chronic renal disease, and those more than 24 weeks pregnant were excluded. They reported a failure rate of 30% at 2 weeks. Four of the 11 failures continued to have bacteriuria after treatment with a 5-day course. In a randomised study, Gertsner et al. (1989) claimed a better eradication rate for single dose amoxicillin versus a 4-day course of the drug. Four different single-dose schedules were investigated by Harris et al. (1982) , with follow-up after 5 days. The failure rate ranged from 25 to 29%, except for cefalexin which showed a rate of 45%. All patients who failed with a single dose were then treated with the same agent for 10 days. The recurrence rate after therapy was 5% or less in all 4 study groups, with or without treatment. Jakobi et al. (1987) compared single doses of amoxicillin and cefalexin, and reported failure rates of 22% at 1 week and 34% at 4 weeks. Seven of 8 patients responded to a 7-day course using the same drug. Masterton et al. (1985) demonstrated failure rates of 11.8 and 19%, respectively, after 1 and 6 weeks' follow-up after treatment with a single 3g dose of amoxicillin or a 7-day course of ampicillin. McFadyen et al. (1987) compared, in a randomised, double-blind study, single dose and ' 3 days' treatment with cefalexin, and found comparable outcomes after 2 to 3 weeks. Six-weekfailure rates were 47 and 38% after a single dose or a 6-day course of sulfamethizole in an open randomised trial (Olsen et al. 1989) .
Although the results obtained with cotrimoxazole (trimethoprim/sulfamethoxazole) and trimethoprim appeared promising because of high bacteriuria eradication rates (Bailey 1984; Bailey et al. 1986 ), these reports were not included in the table because trimethoprim, a folate synthesis inhibitor, is not recommended for routine use in pregnancy. However, experience with this drug in pregnancy based on placebo-controlled studies and some case reports has failed to reveal an increase in fetal abnormalities (Briggs et al. 1990 ).
Although single-dose therapy using 'different agents appears to be efficacious (Campbell-Brown & McFadyen 1983; Gerstner et al. 1989; Harris et al. 1982; Jakobi et al. 1987; McFadyen et al. 1987; Masterton et al. 1985; Olsen et al.1989) , it is difficult to compare the studies. There is lack of uniformity in diagnostic criteria, inclusion and exclusion criteria, method of randomisation, stratification for risk factors which may affect therapeutic outcome, description of outcome measures, duration of follow-up, and adverse effects to the mother as well as the fetus. In spite of these shortcomings, single-dose or short term therapy may provide the advantages of better compliance, reduced cost, and lower incidence of bacterial resistance development [thus reducing the problem of perinatal resistant organisms (Anderson et al. 1979 ) and of superinfection (Rubin et al. 1980) ]. Single doses also appear to be better tolerated than longer courses. The frequency of adverse effects with single doses of amoxicillin 3g was 4% compared with 13% in patients receiving a 4-day course of 750mg of the drug every 8 hours (Gerstner et al. 1989 ). Considering the above and a failure rate of 10 to 40%, which is comparable to that oflonger term therapy, it appears that a single-dose approach should be strongly considered as the initial treatment. If bacteriuria persists during follow-up, the patient should be treated with a 7-day or longer course of antimicrobial therapy. {j-Lactam drugs (e.g. amoxicillin 3g or cefalexin 2g) are preferable for both single dose and repeat treatment because of their known safety in pregnancy. For patients allergic to penicillin, sulfafurazole (sulfisoxazole) 2g or nitrofurantoin 200mg are acceptable. Cotrimoxazole (trimethoprim 320mg plus sulfamethoxazole 1600mg) or trimethoprim 600mg may be used with caution.
Symptomatic Urinary Tract Infection
Acute cystitis and acute pyelonephritis occur in approximately I to 2% of pregnant women (McNeeley 1988) . Acute cystitis can be treated safely with an oral agent as in the case of nonpregnant women.
Acute pyelonephritis is diagnosed clinically by the presence of costovertebral tenderness, fever, ri-gor, pyuria and bacteriuria. Women with urinary tract infection and accompanying bacteraemia are also considered to have upper urinary tracy infection. When acute pyelonephritis in pregnancy is suspected , the patient should be hospitalised. Urine and blood cultures should be obtained before starting empirically with systemic antimicrobial therapy. The primary goal of therapy is to prevent complications to the mother and fetus, with a secondary goal of reducing the chance of recurrence by eradicating bacteriuria.
The choice of antimicrobial agent should be based on clinical experience in safety and efficacy to the mother and fetus. Ampicillin has been recommended as the preferred drug because it is safe and effective in pregnancy (Krieger 1986; MeNeeley 1988) . Unfortunately, increasing resistance to ampicillin and sulphonamides has been reported (Johnson & Stamm 1989; Tan & File 1990 ). Amoxicillin/clavulanic acid has increased antimicrobial spectrum and will cover many isolates resistant to ampicillin.
Because of the unpredictability of the infecting microorganism and its antimicrobial susceptibility pattern, intravenous antimicrobial agents with broader coverage should be used for empirical coverage (File & Tan 1986 ). Uriedopenicillins (e.g. mezlocillin, piperacillin), third generation cephalosporins, or a ,B-Iactam/,B-Iactamase inhibitor combination (e.g. ticarcillin/clavulanic acid) with or without gentamicin should be started empirically when the physician is unsure if the patient has acute cystitis or pyelonephritis. Acute cystitis can be treated safely with an oral agent as in the case of the nonpregnant woman. Gentamicin may cause fetal ototoxicity and should be used with caution. When the antimicrobial susceptibility results are available, a more specific antimicrobial agent should be substituted. When the patient is clinically stable and is tolerating food well, oral therapy may be used. A 10-to 14-day course is recommended (Patterson & Andriole 1987) , although a shorter course of therapy has been shown to be effective (Faro et al. 1984) . Urine culture should be obtained weekly for 4 weeks then monthly until term. If a culture is positive, a repeat 977 course of 2 weeks' treatment or a suppressive therapy may be considered. A single 50 to 100mg dose of nitrofurantoin, single-dose cefalexin or cefradine 250mg, or any 'safe' antimicrobial agent effective against the isolated organism is acceptable for suppressive therapy. Harris and Gilstrap (1974) reported a 60% recurrence rate (including both reinfections and relapses) in pregnant women who Screening test for -=. 
Recommendations
The safety profile for the mother and fetus is extremely important when a therapeutic agent is considered for bacteriuria in pregnancy. Unfortunately, human data on drug toxicity to mother and fetus are usually limited, and animal studies on the toxic effect to the fetus are notoriously unreliable (Krieger 1986 ). Chow and Jewesson (1985) reviewed the pharmacokinetics and safety of antimicrobial agents in pregnancy. Table II summarises the safety of selected drugs which are used for urinary tract infection. As a general rule, the penicillins, cephalosporins, and nitrofurantoin are considered safe; tetracyclines and quinolones are generally contraindicated; and trimethoprim and cotrimoxazole are not recommended.
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did not receive suppressive therapy after acute pyelonephritis. Close surveillance may be indicated, with suppressive therapy reserved for those with underlying renal disease (Lenke & Stamm 1986; Lenke et al. 1983) .
Another approach in pregnant women with recurrent urinary tract infection caused by susceptible organisms is to use postcoital prophylaxis (Pfau & Sacks 1992) . Symptomatic infection should be treated with an appropriate agent for 1 full day, followed, after the urine is sterile, by a single dose of cefalexin 250mg or nitrofurantoin 50mg shortly after intercourse for the remainder of the pregnancy. Although the results appear to be very impressive, this needs to be confirmed.
In addition to antimicrobial treatment, ultrasound may be used to look for urological abnormalities. Intravenous pyelogram and other invasive urological procedures should be deferred until after the pregnancy, unless there is a medical indication such as suspected acute obstructive uropathy, renal abscess or intra-abdominal pathology. To ensure eradication ofthe bacteria, a I-week posttreatment urine culture should be obtained and repeat culture at each visit thereafter. If the bacteriuria recurs, a longer course of therapy and possibly with a different antimicrobial agent should be given. Urine culture should be repeated I week after treatment is discontinued. If urine culture remains positive, suppressive therapy with nitrofurantoin until delivery is recommended. Postcoital prophylaxis with cefalexin or nitrofurantoin throughout the gestational period has been shown to be effective (Pfau & Sacks 1992) . Special attention should be placed on pregnant women with a history of past urinary tract infection, renal abnormality, and diabetes mellitus because of their increased predisposition to symptomatic infection. If the screening urine culture is negative, these patients should be observed closely and a repeat culture is recommended at the beginning of the third trimester. When a patient has urinary symptoms without fever or toxicity, urine culture should be taken and a short course of oral therapy similar to that for asymptomatic bacteriuria should suffice (MeNeeley 1988) . Patients with signs of acute symptomatic infection (fever, chills, and/or flank pain) should be given intravenous therapy until clinical improvement is observed. Oral therapy should be given to complete a 14-day course. Subsequent follow-up is similar to that for asymptomatic bacteriuric patients. When bacteriuria persists in spite of repeated therapy, long term suppressive therapy should be considered individually.
